Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Enzalutamide (MDV3100) is a second-generation androgen receptor antagonist that improves survival in metastatic, castration-resistant prostate cancer (mCRPC). Alternatives include chemotherapy, radiation, immunotherapy and abiraterone. Areas covered: The Phase I/II study showed early evidence of efficacy and determined that fatigue is the dose-limiting toxicity. Two randomized, placebo-controlled trials have demonstrated superiority of enzalutamide 160 mg by mouth daily over placebo in terms of overall survival, radiographic progression-free survival as well as a broad range of secondary and exploratory end points in men who had received previous chemotherapy (AFFIRM) and in those who were chemotherapy naive (PREVAIL). Common side effects include fatigue, arthralgias and constipation. A post hoc analysis from AFFIRM found that enzalutamide is safe and effective in men aged ≥ 75 years. The Phase I/II studies as well as AFFIRM and PREVAIL are described in this review. Expert opinion: Enzalutamide extends overall and progression-free survival and is associated with robust response rates and quality of life benefits in men with mCRPC. Enzalutamide has not been proven to be effective in biochemically relapsed disease or in castration-sensitive prostate cancer. It should not be used in men at high risk for seizure, and patients should be counseled about the increased risk of falls.

Original languageEnglish (US)
Pages (from-to)749-754
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number5
DOIs
StatePublished - Apr 1 2015

Fingerprint

Castration
Prostatic Neoplasms
Safety
Drug Therapy
Disease-Free Survival
Fatigue
Androgen Receptor Antagonists
Placebos
Survival
Arthralgia
Expert Testimony
Constipation
Immunotherapy
Mouth
MDV 3100
Seizures
Randomized Controlled Trials
Quality of Life
Radiation

Keywords

  • Androgen receptor
  • Castration-resistant prostate cancer
  • Enzalutamide
  • MDV3100

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. / Graff, Julie; Gordon, Max J.; Beer, Tomasz (Tom).

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 5, 01.04.2015, p. 749-754.

Research output: Contribution to journalArticle

@article{ef830239fdf94e1b942e521e6f660ed3,
title = "Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer",
abstract = "Introduction: Enzalutamide (MDV3100) is a second-generation androgen receptor antagonist that improves survival in metastatic, castration-resistant prostate cancer (mCRPC). Alternatives include chemotherapy, radiation, immunotherapy and abiraterone. Areas covered: The Phase I/II study showed early evidence of efficacy and determined that fatigue is the dose-limiting toxicity. Two randomized, placebo-controlled trials have demonstrated superiority of enzalutamide 160 mg by mouth daily over placebo in terms of overall survival, radiographic progression-free survival as well as a broad range of secondary and exploratory end points in men who had received previous chemotherapy (AFFIRM) and in those who were chemotherapy naive (PREVAIL). Common side effects include fatigue, arthralgias and constipation. A post hoc analysis from AFFIRM found that enzalutamide is safe and effective in men aged ≥ 75 years. The Phase I/II studies as well as AFFIRM and PREVAIL are described in this review. Expert opinion: Enzalutamide extends overall and progression-free survival and is associated with robust response rates and quality of life benefits in men with mCRPC. Enzalutamide has not been proven to be effective in biochemically relapsed disease or in castration-sensitive prostate cancer. It should not be used in men at high risk for seizure, and patients should be counseled about the increased risk of falls.",
keywords = "Androgen receptor, Castration-resistant prostate cancer, Enzalutamide, MDV3100",
author = "Julie Graff and Gordon, {Max J.} and Beer, {Tomasz (Tom)}",
year = "2015",
month = "4",
day = "1",
doi = "10.1517/14656566.2015.1016911",
language = "English (US)",
volume = "16",
pages = "749--754",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer

AU - Graff, Julie

AU - Gordon, Max J.

AU - Beer, Tomasz (Tom)

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: Enzalutamide (MDV3100) is a second-generation androgen receptor antagonist that improves survival in metastatic, castration-resistant prostate cancer (mCRPC). Alternatives include chemotherapy, radiation, immunotherapy and abiraterone. Areas covered: The Phase I/II study showed early evidence of efficacy and determined that fatigue is the dose-limiting toxicity. Two randomized, placebo-controlled trials have demonstrated superiority of enzalutamide 160 mg by mouth daily over placebo in terms of overall survival, radiographic progression-free survival as well as a broad range of secondary and exploratory end points in men who had received previous chemotherapy (AFFIRM) and in those who were chemotherapy naive (PREVAIL). Common side effects include fatigue, arthralgias and constipation. A post hoc analysis from AFFIRM found that enzalutamide is safe and effective in men aged ≥ 75 years. The Phase I/II studies as well as AFFIRM and PREVAIL are described in this review. Expert opinion: Enzalutamide extends overall and progression-free survival and is associated with robust response rates and quality of life benefits in men with mCRPC. Enzalutamide has not been proven to be effective in biochemically relapsed disease or in castration-sensitive prostate cancer. It should not be used in men at high risk for seizure, and patients should be counseled about the increased risk of falls.

AB - Introduction: Enzalutamide (MDV3100) is a second-generation androgen receptor antagonist that improves survival in metastatic, castration-resistant prostate cancer (mCRPC). Alternatives include chemotherapy, radiation, immunotherapy and abiraterone. Areas covered: The Phase I/II study showed early evidence of efficacy and determined that fatigue is the dose-limiting toxicity. Two randomized, placebo-controlled trials have demonstrated superiority of enzalutamide 160 mg by mouth daily over placebo in terms of overall survival, radiographic progression-free survival as well as a broad range of secondary and exploratory end points in men who had received previous chemotherapy (AFFIRM) and in those who were chemotherapy naive (PREVAIL). Common side effects include fatigue, arthralgias and constipation. A post hoc analysis from AFFIRM found that enzalutamide is safe and effective in men aged ≥ 75 years. The Phase I/II studies as well as AFFIRM and PREVAIL are described in this review. Expert opinion: Enzalutamide extends overall and progression-free survival and is associated with robust response rates and quality of life benefits in men with mCRPC. Enzalutamide has not been proven to be effective in biochemically relapsed disease or in castration-sensitive prostate cancer. It should not be used in men at high risk for seizure, and patients should be counseled about the increased risk of falls.

KW - Androgen receptor

KW - Castration-resistant prostate cancer

KW - Enzalutamide

KW - MDV3100

UR - http://www.scopus.com/inward/record.url?scp=84924351297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924351297&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1016911

DO - 10.1517/14656566.2015.1016911

M3 - Article

C2 - 25687355

AN - SCOPUS:84924351297

VL - 16

SP - 749

EP - 754

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -